Nuvation Bio (NUVB) Return on Capital Employed (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Return on Capital Employed of 28.71% for Q1 2026, up 10743.0% year-over-year from N/an in Q1 2025, and up 30.46% quarter-over-quarter from 41.29% in Q4 2025.
Nuvation Bio (NUVB) Return on Capital Employed (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Return on Capital Employed for 7 consecutive years, with 28.71% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 10743.0% year-over-year to 28.71%; the TTM figure through Mar 2026 stood at 28.71% (up 10743.0% YoY), while the FY2025 annual figure was 43.89%, up 6947.0% from the prior year.
- Return on Capital Employed grew to 28.71% in Q1 2026 per NUVB's latest filing, from 41.29% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 13.61% in Q1 2022 and bottomed at 136.15% in Q1 2025.
- Historically, Return on Capital Employed has averaged 45.02% across 5 years, with a median of 18.14% in 2022.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 12060 bps — and 2026, when it surged 10743 bps.
- Nuvation Bio's Return on Capital Employed stood at 17.97% in 2022, then increased by 9 bps to 16.31% in 2023, then tumbled by 630 bps to 119.04% in 2024, then soared by 65 bps to 41.29% in 2025, then surged by 30 bps to 28.71% in 2026.
- Business Quant data shows NUVB's Return on Capital Employed at 28.71% in Q1 2026, 41.29% in Q4 2025, and 41.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | -23.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -23.30% |
| Mar 31, 2026 | -28.71% |
| Dec 31, 2025 | -41.29% |
| Sep 30, 2025 | -41.88% |
| Jun 30, 2025 | -44.61% |
| Mar 31, 2025 | -136.15% |
| Dec 31, 2024 | -119.04% |
| Sep 30, 2024 | -106.75% |
| Jun 30, 2024 | -97.27% |
| Mar 31, 2024 | -15.54% |
| Dec 31, 2023 | -16.31% |
| Sep 30, 2023 | -16.67% |
| Jun 30, 2023 | -16.72% |
| Mar 31, 2023 | -18.11% |
| Dec 31, 2022 | -17.97% |
| Sep 30, 2022 | -18.14% |
| Jun 30, 2022 | -16.58% |
| Mar 31, 2022 | -13.61% |
| Dec 31, 2021 | -12.12% |
| Sep 30, 2021 | -8.42% |